Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 30903103
Turunen SP, et al. (2019) FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis. Cell Death Differ 30903103
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T177-p - MST1 (human)
Modsite: VAGQLTDtMAkRNtV SwissProt Entrez-Gene
Orthologous residues
MST1 (human): T177‑p, MST1 iso2 (human): T177‑p, MST1 (mouse): T177‑p, MST1 (rat): T177‑p

T183-p - MST1 (human)
Modsite: DtMAkRNtVIGTPFW SwissProt Entrez-Gene
Orthologous residues
MST1 (human): T183‑p, MST1 iso2 (human): T183‑p, MST1 (mouse): T183‑p, MST1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), MDA-MB-453 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE MST1 (human) autophosphorylation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGFR4 (human) decrease FGFR4-siRNA increase
serum decrease
mutation FGFR4 (human) increase MST1 Y433F mutant
BLU9931 increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced
Effect of modification (process):  apoptosis, induced

S320-p - MST1 (human)
Modsite: DQDDEENsEEDEMDs SwissProt Entrez-Gene
Orthologous residues
MST1 (human): S320‑p, MST1 iso2 (human): S320‑p, MST1 (mouse): S320‑p, MST1 (rat): S320‑p

S410-p - MST1 (human)
Modsite: EkENQINsFGksVPG SwissProt Entrez-Gene
Orthologous residues
MST1 (human): S410‑p, MST1 iso2 (human): S410‑p, MST1 (mouse): S410‑p, MST1 (rat): S410‑p
Characterization
Methods used to characterize site in vivo mass spectrometry (in vitro), phospho-antibody

Y433-p - MST1 (human)
Modsite: kIPQDGDyEFLksWt SwissProt Entrez-Gene
Orthologous residues
MST1 (human): Y433‑p, MST1 iso2 (human): Y433‑p, MST1 (mouse): Y433‑p, MST1 (rat): Y433‑p
Characterization
Methods used to characterize site in vivo mass spectrometry (in vitro), mutation of modification site, phospho-antibody
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  COS (fibroblast), MDA-MB-231 (breast cell), T47D (breast cell)
Cellular systems studied:  cell lines
Species studied:  green monkey, human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE FGFR4 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE FGFR4 (human) phospho-antibody, siRNA inhibition of enzyme, transfection of wild-type enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease FGFR1-siRNA inhibits
Downstream Regulation
Effect of modification (function):  enzymatic activity, inhibited, phosphorylation
Associated Diseases
Diseases Alterations Comments
HER2 positive breast cancer decreased